Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in ALK+ NSCLC after Alectinib or Ceritinib
NCT03535740Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by ARIAD Pharmaceuticals, Inc.. Started Jan 2019; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03535740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535740.